Combined oro-caecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-caecal transit, not small intestinal bacterial overgrowth in patients with IBS.
about
Intestinal microbiota in functional bowel disorders: a Rome foundation reportMechanism-Oriented Therapy of Irritable Bowel SyndromeProfile of rifaximin and its potential in the treatment of irritable bowel syndromeAbdominal bloating: pathophysiology and treatmentUpper gastrointestinal microbiota and digestive diseasesReview article: the aetiology, diagnosis, mechanisms and clinical evidence for food intoleranceReview article: the assessment and management of chronic severe gastrointestinal dysmotility in adultsHow to interpret hydrogen breath testsLeukocyte-subset counts in idiopathic parkinsonism provide clues to a pathogenic pathway involving small intestinal bacterial overgrowth. A surveillance study.Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months.Diagnosis and management of small intestinal bacterial overgrowth.Breath tests and irritable bowel syndrome.Rifaximin for small intestinal bacterial overgrowth in patients without irritable bowel syndromeSmall Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome: A Bridge between Functional Organic DichotomyIrritable bowel syndrome: a clinical reviewThe prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: relationship with irritable bowel syndrome.Irritable bowel syndrome and small intestinal bacterial overgrowth: meaningful association or unnecessary hype.Fermentable oligosaccharides, disaccharides, monosaccharides and polyols: role in irritable bowel syndrome.Autoimmunity Links Vinculin to the Pathophysiology of Chronic Functional Bowel Changes Following Campylobacter jejuni Infection in a Rat Model.Comparison of the antibacterial activity of essential oils and extracts of medicinal and culinary herbs to investigate potential new treatments for irritable bowel syndrome.No difference in small bowel microbiota between patients with irritable bowel syndrome and healthy controls.Overgrowth of the indigenous gut microbiome and irritable bowel syndrome.Review article: evidence for the role of gut microbiota in irritable bowel syndrome and its potential influence on therapeutic targets.Predisposing factors for positive D-Xylose breath test for evaluation of small intestinal bacterial overgrowth: a retrospective study of 932 patientsDetermination of rifaximin treatment period according to lactulose breath test values in nonconstipated irritable bowel syndrome subjects.Methods for the assessment of small-bowel and colonic transit.Predicting a Response to Antibiotics in Patients with the Irritable Bowel Syndrome.Targeted therapies for diarrhea-predominant irritable bowel syndrome.Small intestinal bacterial overgrowth is associated with irritable bowel syndrome and is independent of proton pump inhibitor usage.Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome.New and Emerging Treatment Options for Irritable Bowel Syndrome.Ileocecal valve dysfunction in small intestinal bacterial overgrowth: a pilot studyEffects of Rifaximin on Transit, Permeability, Fecal Microbiome, and Organic Acid Excretion in Irritable Bowel Syndrome.Small Intestinal Bacterial Overgrowth in Patients with Irritable Bowel Syndrome: Clinical Characteristics, Psychological Factors, and Peripheral CytokinesAltered Colonic Bacterial Fermentation as a Potential Pathophysiological Factor in Irritable Bowel Syndrome.Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome.Measurement of Gastrointestinal and Colonic Motor Functions in Humans and AnimalsPoor reproducibility of breath hydrogen testing: Implications for its application in functional bowel disorders.The role of rifaximin therapy in patients with irritable bowel syndrome without constipation.Rifaximin for the treatment of irritable bowel syndrome.
P2860
Q24631357-A0971FA3-255E-4E37-B39E-883DEAE352CCQ26747875-3E9F5B76-6174-4517-B7D5-134DB9083B75Q26829363-85F8520D-49CC-4ADF-8FE7-8E5EB9713D47Q26851622-45E46DF1-932F-41BA-AB77-E71C2F8C5DFDQ27002380-54D19AC3-5A9F-453D-9987-2285132A1033Q27025168-7A85890D-6AB9-486B-A500-5DA5F8147669Q27030666-453576B4-7B89-4A11-B104-EE28ABD4C372Q28246206-18F1338F-899F-42B3-9A6B-0F8DC473CC79Q30528442-7C782E4F-7A4A-4275-893D-3BC3A2EAA4F9Q33456102-CBAEA514-B0F4-4683-AE2C-759A7391E425Q33457767-E2BD7FE8-80DF-482A-A3B0-1623AA3E9F36Q33462070-73BA7FFE-3A72-4F4C-8079-9186CB2D4EFBQ33463153-DB6A4987-6AEB-4FBC-ADD0-8BB7B8974476Q33469991-B382D627-07AF-4E19-8E41-1430C3C4493DQ34168517-4E69AEAB-EF53-49BD-9AEA-3A58CFC2879BQ34248518-5701ACCE-BD38-4B19-B993-A76E2193DDB2Q34410012-7341DE3A-BC3F-4F7A-87F2-8C38690B2A21Q34420107-E1EE48FC-F2FD-45A1-ADF5-6F39260DB549Q34449503-F396E723-3D20-46DC-AEF0-70C2083F7F1AQ34454007-456883DA-229A-4B8D-89D9-404BF6D40ACFQ35089445-DF65CE0D-6B44-413D-BF08-490AB12E263BQ35120395-5676E0A6-9EAF-4691-B62B-7289944A9654Q35130485-B41F4A04-26A3-4D29-8020-023F6BDD4E81Q35472961-CB0D07FC-70AD-40E7-A553-3DDECAA0FCBFQ35649153-C7BB427C-4608-4E57-B87F-BF2F16D1D04DQ35724278-E430F106-EFAD-40EC-AEF6-E3DB2842492EQ35771310-CAC63A0F-FBF4-4200-8AA2-8AF0C5FC1198Q36065945-8140F1D3-8459-46BE-AF0F-3256B1E915A3Q36073385-FD72208F-C44F-48EB-B2E6-1C5CEF2C00DBQ36160305-2E94E79D-CDAB-4DCC-BB48-87A59BEA94F3Q36180769-9BA6F622-0EC2-4E73-8BFA-ED409B150114Q36461018-A6DF1222-A441-4264-996C-18B553FEAE30Q36970524-3B99AF99-7B82-40B8-AEBF-F59C12DAC92EQ37030459-21B9E69A-2208-40B2-A4E6-FED4344EA21AQ37172906-64D7A441-D941-4522-AC68-3B25F3CE202BQ37234770-90AC0547-5105-4401-B4EC-48B7EA6FC4B1Q37261844-19113162-F254-40EA-BFB9-D3EA14443D12Q37698561-EB1ABD4F-0886-45A0-B8AD-D6EF7CD7803EQ37903847-E4CE3AEC-22AC-467A-B8B0-2C5AFBC78847Q37976477-86A59EA7-CB6B-48D1-873E-5B337139F820
P2860
Combined oro-caecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-caecal transit, not small intestinal bacterial overgrowth in patients with IBS.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Combined oro-caecal scintigrap ...... ergrowth in patients with IBS.
@ast
Combined oro-caecal scintigrap ...... ergrowth in patients with IBS.
@en
Combined oro-caecal scintigrap ...... ergrowth in patients with IBS.
@nl
type
label
Combined oro-caecal scintigrap ...... ergrowth in patients with IBS.
@ast
Combined oro-caecal scintigrap ...... ergrowth in patients with IBS.
@en
Combined oro-caecal scintigrap ...... ergrowth in patients with IBS.
@nl
prefLabel
Combined oro-caecal scintigrap ...... ergrowth in patients with IBS.
@ast
Combined oro-caecal scintigrap ...... ergrowth in patients with IBS.
@en
Combined oro-caecal scintigrap ...... ergrowth in patients with IBS.
@nl
P2093
P921
P356
P1433
P1476
Combined oro-caecal scintigrap ...... ergrowth in patients with IBS.
@en
P2093
Frank Cheeseman
Stephen Vanner
P304
P356
10.1136/GUT.2009.205476
P407
P577
2010-11-26T00:00:00Z